AstraZeneca on Tuesday said it has requested an emergency use authorization (EUA) grant from the U.S. Food and Drug Administration for its Covid-19 prophylaxis drug, a move that comes over a month after the antibody cocktail was shown to be effective in preventing symptoms among high-risk individuals who received the drug prior to exposure.
The antibody therapy called AZD7442 was 77% effective in reducing the risk of developing Covid-19 symptoms among people who received the drug as a preventive measure, AstraZeneca said in a press release, citing its Phase III trail featuring over 5,000 participants.
According to the drugmaker, the antibody cocktail could be used to protect people who may not develop a robust immune response to Covid-19 vaccines.
Unlike a vaccine which helps a recipient’s immune system build its own antibodies and infection-fighting cells against the virus, antibody treatments directly use lab-made antibodies that can linger in a person for months and protect them against infection.
The company also noted that trials performed ‘in Vitro’ (in test tubes) showed that the drug was able to neutralize emergent Covid variants, including delta and mu.
The drugmaker added that supply agreements for AZD7442 are ongoing with the United States and other governments around the world.
This is a developing story.
Full coverage and live updates on the Coronavirus